Published in Transplantation on September 27, 2007
Current and Future Treatment Strategies for Patients with Advanced Hepatocellular Carcinoma: Role of mTOR Inhibition. Liver Cancer (2012) 0.98
Malignancy after renal transplantation: the role of immunosuppression. Nat Rev Nephrol (2010) 0.98
Irreversible liver failure: treatment by transplantation: part 3 of a series on liver cirrhosis. Dtsch Arztebl Int (2013) 0.83
PI3Kδ inhibition augments the efficacy of rapamycin in suppressing proliferation of Epstein-Barr virus (EBV)+ B cell lymphomas. Am J Transplant (2013) 0.81
Antineoplastic effects of mammalian target of rapamycine inhibitors. World J Transplant (2012) 0.80
Neoplastic disease after liver transplantation: Focus on de novo neoplasms. World J Gastroenterol (2015) 0.77
Everolimus immunosuppression reduces the serum expression of fibrosis markers in liver transplant recipients. World J Transplant (2014) 0.76
Multiple indications for everolimus after liver transplantation in current clinical practice. World J Transplant (2014) 0.75
Everolimus and Malignancy after Solid Organ Transplantation: A Clinical Update. J Transplant (2016) 0.75
Cancer and transplantation intersect at the mammalian target of rapamycin. Transplantation (2007) 0.75
Efficacy and safety of anticoagulation on patients with cirrhosis and portal vein thrombosis. Clin Gastroenterol Hepatol (2012) 4.62
Esophageal eosinophilic infiltration responds to proton pump inhibition in most adults. Clin Gastroenterol Hepatol (2010) 3.43
Rebleeding prophylaxis improves outcomes in patients with hepatocellular carcinoma. A multicenter case-control study. Hepatology (2013) 3.31
The estrogenic effect of bisphenol A disrupts pancreatic beta-cell function in vivo and induces insulin resistance. Environ Health Perspect (2006) 2.59
Endoscopic treatment versus endoscopic plus pharmacologic treatment for acute variceal bleeding: a meta-analysis. Hepatology (2002) 2.49
A new scoring system for prognostic stratification of patients with alcoholic hepatitis. Am J Gastroenterol (2008) 2.35
Meta-analysis: Combination endoscopic and drug therapy to prevent variceal rebleeding in cirrhosis. Ann Intern Med (2008) 2.05
Patients with cirrhosis and bare-stent TIPS may have increased risk of hepatocellular carcinoma. Hepatology (2005) 2.04
Low doses of bisphenol A and diethylstilbestrol impair Ca2+ signals in pancreatic alpha-cells through a nonclassical membrane estrogen receptor within intact islets of Langerhans. Environ Health Perspect (2005) 1.79
Low doses of the endocrine disruptor bisphenol-A and the native hormone 17beta-estradiol rapidly activate transcription factor CREB. FASEB J (2002) 1.76
A meta-analysis of transjugular intrahepatic portosystemic shunt versus paracentesis for refractory ascites. J Hepatol (2005) 1.73
Prevalence of BK virus replication among recipients of solid organ transplants. Clin Infect Dis (2005) 1.66
Physiology of the pancreatic alpha-cell and glucagon secretion: role in glucose homeostasis and diabetes. J Endocrinol (2008) 1.66
Hepatic venous pressure gradient and prognosis in patients with acute variceal bleeding treated with pharmacologic and endoscopic therapy. J Hepatol (2007) 1.60
Propranolol plus placebo versus propranolol plus isosorbide-5-mononitrate in the prevention of a first variceal bleed: a double-blind RCT. Hepatology (2003) 1.54
Epidemiology and outcome of infections in human immunodeficiency virus/hepatitis C virus-coinfected liver transplant recipients: a FIPSE/GESIDA prospective cohort study. Liver Transpl (2012) 1.53
Simvastatin lowers portal pressure in patients with cirrhosis and portal hypertension: a randomized controlled trial. Gastroenterology (2009) 1.49
Cannabinoid receptors regulate Ca(2+) signals and insulin secretion in pancreatic beta-cell. Cell Calcium (2006) 1.31
Comparison of transcatheter arterial embolization and surgery for treatment of bleeding peptic ulcer after endoscopic treatment failure. J Vasc Interv Radiol (2004) 1.31
Influence of hepatic venous pressure gradient on the prediction of survival of patients with cirrhosis in the MELD Era. Hepatology (2005) 1.22
Bisphenol-A acts as a potent estrogen via non-classical estrogen triggered pathways. Mol Cell Endocrinol (2011) 1.21
Efficacy and safety of sorafenib in combination with mammalian target of rapamycin inhibitors for recurrent hepatocellular carcinoma after liver transplantation. Liver Transpl (2012) 1.16
Role of leptin in the pancreatic β-cell: effects and signaling pathways. J Mol Endocrinol (2012) 1.15
Incidence, prevalence, and clinical significance of abnormal hematologic indices in compensated cirrhosis. Clin Gastroenterol Hepatol (2009) 1.14
Early noninvasive measurement of the indocyanine green plasma disappearance rate accurately predicts early graft dysfunction and mortality after deceased donor liver transplantation. Liver Transpl (2009) 1.13
HVR-1 quasispecies modifications occur early and are correlated to initial but not sustained response in HCV-infected patients treated with pegylated- or standard-interferon and ribavirin. J Hepatol (2004) 1.08
Transglutaminase type II plays a protective role in hepatic injury. Am J Pathol (2003) 1.06
Comparison of transjugular intrahepatic portosystemic shunt dysfunction in PTFE-covered stent-grafts versus bare stents. Eur J Radiol (2005) 1.05
Hepatic and systemic haemodynamic changes after MARS in patients with acute on chronic liver failure. Liver Int (2003) 1.05
Hepatic insulin resistance is associated with increased apoptosis and fibrogenesis in nonalcoholic steatohepatitis and chronic hepatitis C. J Hepatol (2010) 1.03
Endogenous levels of mRNA for IFNs and IFN-related genes in hepatic biopsies of chronic HCV-infected and non-alcoholic steatohepatitis patients. J Med Virol (2003) 1.02
TIPS versus drug therapy in preventing variceal rebleeding in advanced cirrhosis: a randomized controlled trial. Hepatology (2002) 1.01
Autophagy protects cells from HCV-induced defects in lipid metabolism. Gastroenterology (2011) 1.01
Risk factors for hepatic encephalopathy in patients with cirrhosis and refractory ascites: relevance of serum sodium concentration. Liver Int (2010) 1.01
Antiviral therapy decreases hepatic venous pressure gradient in patients with chronic hepatitis C and advanced fibrosis. Am J Gastroenterol (2006) 0.97
Rapid regulation of K(ATP) channel activity by 17{beta}-estradiol in pancreatic {beta}-cells involves the estrogen receptor {beta} and the atrial natriuretic peptide receptor. Mol Endocrinol (2009) 0.96
Value of the hepatic venous pressure gradient to monitor drug therapy for portal hypertension: a meta-analysis. Am J Gastroenterol (2007) 0.95
Surgical complications of submandibular gland excision. Acta Otorrinolaringol Esp (2011) 0.94
Response to steroids in de novo autoimmune hepatitis after liver transplantation. Hepatology (2002) 0.94
Portal hypertension-related complications after acute portal vein thrombosis: impact of early anticoagulation. Clin Gastroenterol Hepatol (2008) 0.93
Multidisciplinary strategies to improve treatment outcomes in hepatocellular carcinoma: a European perspective. Eur J Gastroenterol Hepatol (2013) 0.93
Estrogen and xenoestrogen actions on endocrine pancreas: from ion channel modulation to activation of nuclear function. Steroids (2004) 0.93
Differential contribution of hepatitis C virus NS5A and core proteins to the induction of oxidative and nitrosative stress in human hepatocyte-derived cells. J Hepatol (2005) 0.92
The extent of the collateral circulation influences the postprandial increase in portal pressure in patients with cirrhosis. Gut (2006) 0.91
Serum levels of soluble vascular cell adhesion molecule are related to hyperdynamic circulation in patients with liver cirrhosis. Liver Int (2008) 0.90
Granulocyte colony-stimulating factor improves deficient in vitro neutrophil transendothelial migration in patients with advanced liver disease. Clin Diagn Lab Immunol (2002) 0.90
Rapid endocrine disruption: environmental estrogen actions triggered outside the nucleus. J Steroid Biochem Mol Biol (2006) 0.89
Endotipsitis: an emerging prosthetic-related infection in patients with portal hypertension. Diagn Microbiol Infect Dis (2004) 0.89
Accumulation of dysfunctional effector CD8+ T cells in the liver of patients with chronic HCV infection. J Hepatol (2005) 0.88
Validation of noninvasive indices of global systolic function in patients with normal and abnormal loading conditions: a simultaneous echocardiography pressure-volume catheterization study. Circ Cardiovasc Imaging (2013) 0.87
Disentangling the molecular mechanisms of action of endogenous and environmental estrogens. Pflugers Arch (2004) 0.87
Prevalence of portal hypertensive duodenopathy in cirrhosis: clinical and haemodynamic features. Eur J Gastroenterol Hepatol (2006) 0.86
Prognostic value of hepatic venous pressure gradient in patients with compensated chronic hepatitis C-related cirrhosis. Scand J Gastroenterol (2012) 0.85
Predicting portal hypertension and variceal bleeding using non-invasive measurements of metabolic variables. Ann Hepatol (2013) 0.85
Increased soluble CD36 is linked to advanced steatosis in nonalcoholic fatty liver disease. Eur J Clin Invest (2013) 0.84
Cardiac dysfunction during liver transplantation: incidence and preoperative predictors. Transplantation (2008) 0.84
Comparison of MELD, HVPG, and their changes to predict clinically relevant endpoints in cirrhosis. Scand J Gastroenterol (2012) 0.84
Risk factors for developing de novo autoimmune hepatitis associated with anti-glutathione S-transferase T1 antibodies after liver transplantation. Liver Transpl (2009) 0.83
Impact of donor and recipient CYP3A5 and ABCB1 genetic polymorphisms on tacrolimus dosage requirements and rejection in Caucasian Spanish liver transplant patients. J Clin Pharmacol (2013) 0.83
Role of estrogen receptors alpha, beta and GPER1/GPR30 in pancreatic beta-cells. Front Biosci (Landmark Ed) (2011) 0.83
Oral probiotic VSL#3 attenuates the circulatory disturbances of patients with cirrhosis and ascites. Liver Int (2014) 0.83
Serum angiopoietin-2 level as a predictor of tumor invasiveness in patients with hepatocellular carcinoma. Scand J Gastroenterol (2012) 0.82
[Laryngeal chondronecrosis following radiotherapy and concurrent chemotherapy]. Acta Otorrinolaringol Esp (2008) 0.81